AGA Family of Websites:
Clinical Practice Update

Management of inflammatory bowel disease (IBD) during the COVID-19 pandemic

Timely expert recommendations regarding the management of patients with inflammatory bowel disease (IBD) during the coronavirus pandemic. 

Guideline Tool kits

Members only access the guideline tool kits

Best practice advice

1. COVID-19 is the disease caused by the SARS-CoV-2 virus, but patients with IBD do not appear to be at a higher risk for infection with SARS-CoV-2 or development of COVID-19.

2. Patients with IBD who do not have infection with SARS-CoV-2 should not discontinue their IBD therapies and should continue infusion schedules at appropriate infusion centers.

3. Patients with IBD who have known SARS-CoV-2 but have not developed COVID-19 should hold thiopurines, methotrexate and tofacitinib. Dosing of biological therapies should be delayed for two weeks of monitoring for symptoms of COVID-19.

4. Patients with IBD who develop COVID-19 should hold thiopurines, methotrexate, tofacitinib and biological therapies during the viral illness. These can be restarted after complete symptom resolution or, if available, when follow-up viral testing is negative or serologic tests demonstrate the convalescent stage of illness.

5. The severity of the COVID-19 and the severity of the IBD should result in careful risk-benefit assessments regarding treatments for COVID-19 and escalating treatments for IBD.

6. Please submit cases of IBD and confirmed COVID-19 to the SECURE-IBD registry at